Key Results
Benralizumab and mepolizumab significantly (P<0.001 vs.
positive control) prevented the AHR to histamine (maximal effect
-134.14±14.93% and -108.29±32.16%, respectively), with benralizumab
being 0.73±0.10 logarithm significantly (P<0.05) more potent
than mepolizumab. Benralizumab and mepolizumab significantly
(P<0.001 vs. positive control) inhibited the AHR to transmural
stimulation and mechanical stress. Benralizumab was 0.45±0.16 logarithm
significantly (P<0.05) more potent than mepolizumab against
AHR to parasympathetic activation. The effect of these agents was
significantly correlated (P<0.001) with increased levels of
cAMP.